

1 **Learnings from the Australian First Few X Household Transmission**

2 **Project for COVID-19**

3

4 Adrian J Marcato<sup>1</sup>, Andrew J Black<sup>2</sup>, James Walker<sup>2,3</sup>, Dylan Morris<sup>2</sup>, Niamh Meagher<sup>1,4</sup>, David J Price<sup>1,4</sup>, Jodie

5 McVernon<sup>1,4,5</sup>, and the Australian FFX Household Transmission Project Group

6

7 <sup>1</sup> Department of Infectious Diseases, The University of Melbourne, at the Peter Doherty Institute for Infection

8 and Immunity, Melbourne, Australia

9 <sup>2</sup> School of Mathematical Sciences, The University of Adelaide, Adelaide, Australia

10 <sup>3</sup> School of Mathematics & Statistics, The University of Melbourne, Melbourne, Australia

11 <sup>4</sup> Centre for Epidemiology & Biostatistics, Melbourne School of Population & Global Health, The University of

12 Melbourne

13 <sup>5</sup> Murdoch Children's Research Institute, Melbourne, Australia

14 **Research in context**

15

16 **Evidence before this study**

17 The emergence of SARS-CoV-2 was initially characterised by uncertainty over key epidemiological, clinical  
18 and virological characteristics of the pathogen. We conducted a prospective household transmission study of  
19 confirmed cases of COVID-19 and their household contacts to collect data to understand severity and household  
20 transmission dynamics in Australia and add to the emerging evidence base for decision making. Large  
21 systematic reviews and meta-analyses of severity and transmission dynamics of SARS-CoV-2 in households  
22 have since been published, although estimates vary by setting.

23

24 **Added value of this study**

25 This is the first multi-jurisdictional prospective household transmission study of its kind for SARS-CoV-2 in  
26 Australia. Australia experienced low epidemic activity during the study period in 2020 due to robust public  
27 health and social measures including extensive PCR testing of symptomatic persons and isolation of all known  
28 contacts of confirmed cases. Hence, we describe the transmission dynamics in our cohort, i.e. in a low incidence  
29 setting and provide estimates of the household secondary attack rate, the relative susceptibility of children  
30 compared to adults, and transmission from children compared to adults.

31

32 **Implications of all the available evidence**

33 Our findings describe the epidemiology of COVID-19 in Australian households in 2020, and demonstrate the  
34 effectiveness of public health measures to limit transmission in this setting. Comparisons to other household  
35 transmission studies must be interpreted in light of the local epidemiology and context including study design,  
36 and sampling methods. Additional research is needed to incorporate genomic and serological data to further  
37 study transmission dynamics in our cohort. Continued development of the FFX study platform in Australia will  
38 enable integration into surveillance systems and help inform targeted public health responses to future  
39 infectious disease emergencies.

40 **Abstract**

41

42 **Background:**

43 First Few “X” (FFX) studies provide a platform to collect the required epidemiological, clinical and virological  
44 data to help address emerging information needs about the COVID-19 pandemic.

45

46 **Methods:**

47 We adapted the WHO FFX protocol for COVID-19 to understand severity and household transmission  
48 dynamics in the early stages of the pandemic in Australia. Implementation strategies were developed for  
49 participating sites; all household members provided baseline epidemiological data and were followed for 14  
50 days from case identification. Household contacts completed symptom diaries and had respiratory swabs taken  
51 at baseline, day 7 and day 14, and day 28 where applicable. We modelled the spread of COVID-19 within  
52 households using a susceptible-exposed-infectious-recovered-type model, and calculated the household  
53 secondary attack rate and key epidemiological parameters.

54

55 **Findings:**

56 96 households with 101 cases and 286 household contacts were recruited into the study between April–October  
57 2020. Forty household contacts tested positive for SARS-CoV-2 in the study follow-up period. Our model  
58 estimated the household secondary attack rate to be 15% (95% CI 8–25%), which scaled up with increasing  
59 household size. Children were less infectious than their adult counterparts but were also more susceptible to  
60 infection.

61

62 **Interpretation:**

63 Our study provides important baseline data characterising the transmission of early SARS-CoV-2 strains from  
64 children and adults in Australia, against which properties of variants of concern can be benchmarked. We  
65 encountered many challenges with respect to logistics, ethics, governance and data management that may have  
66 led to biases in our study. Continued efforts to invest in preparedness research will help to test, refine and  
67 further develop Australian FFX study protocols in advance of future outbreaks.

68

69 **Funding:**

70 Australian Government Department of Health

## 71 **Introduction**

72

73 The global spread of the SARS-CoV-2 virus which causes coronavirus disease 2019 (COVID-19) was deemed a  
74 pandemic in March 2020.<sup>1</sup> The emergence and global spread of SARS-CoV-2 was initially characterised by  
75 uncertainty over key epidemiological, clinical and virological characteristics of the pathogen, particularly, its  
76 ability to spread between humans and cause disease in a susceptible population.

77

78 The First Few “X” (FFX) study protocol for COVID-19 published by the World Health Organization (WHO)  
79 provides a platform to collect the required epidemiological, clinical and virological data to help address  
80 emerging information needs about the pandemic.<sup>2-4</sup> The FFX study protocol is one of several protocols  
81 published by WHO as part of their UNITY study framework, which also includes standardised sero-  
82 epidemiological study protocols in household, health care and school settings amongst others.<sup>5,6</sup>

83 In February 2020, the eight Australian state and territory health departments together with the Commonwealth  
84 Department of Health and researchers from the Australian Partnership for Preparedness Research on Infectious  
85 Disease Emergencies (APPRISE) developed a national plan to implement the WHO FFX study protocol for  
86 COVID-19 in Australia.<sup>7,8</sup> The Australian FFX Household transmission project aimed to inform understanding  
87 of local COVID-19 epidemiology in the early epidemic phases, and provide evidence for the development of  
88 guidelines and policy in specifically directing Australia’s ongoing public health response. The findings from this  
89 investigation are described here.

90 Australia’s first epidemic wave in 2020 was driven by returned international travellers and subsequent local  
91 transmission in major urban centres across the country. Public health and social measures were introduced to  
92 control the escalating epidemic, which included: border closures, expanded case management and contact  
93 tracing, and social measures such as density quotients in workplaces and public venues and lockdowns.

94 Mandatory quarantine for returned international travellers was also introduced to reduce the risk of further  
95 importation. These measures drove incident cases in Australia to very low levels, and effective elimination  
96 (sustained periods of zero case incidence) was achieved in many states and territories by May 2020. A national  
97 strategy was set to pursue no community transmission of COVID-19 in the absence of widespread vaccine  
98 coverage.<sup>9</sup>

99 Breaches from the compulsory quarantine system for returned international travellers led to intermittent periods  
100 of local transmission in Australia, particularly in 2020 and the early stages of 2021. Australia's second most  
101 populous state, Victoria, experienced a second epidemic wave of activity from late May 2020 to November  
102 2020.

103 Several Australian states, including New South Wales (Australia's most populous state), Victoria and the  
104 Australian Capital Territory now have established community transmission of SARS-CoV-2 due to the delta  
105 variant. As of December 13<sup>th</sup> 2021, there have been 228,930 confirmed cases of COVID-19 in Australia,  
106 including 2104 deaths. Of these cases, 220,083 were locally acquired and the majority have been confirmed  
107 since June 2021.<sup>10,11</sup>

## 108 **Methods**

### 109 **Study design, ascertainment and eligibility**

110 We adapted the WHO UNITY FFX transmission study protocol for COVID-19, focusing on the household  
111 components, with a goal of recruiting 200 households into the project across participating sites.<sup>3</sup> Participating  
112 sites included New South Wales (NSW; capital Sydney), Victoria (VIC; capital Melbourne), Western Australia  
113 (WA; capital Perth), South Australia (SA; capital Adelaide) and Queensland (QLD; capital Brisbane).

114 These adaptations included separating the study into two components: public health (data and viral swab  
115 collection as part of enhanced public health unit surveillance activities), and; additional research components  
116 (sequencing of positive samples and serology collection and analysis, not presented here), as detailed in  
117 Supplementary Table 1.

118 Laboratory confirmed index cases were recruited from the NSW, WA, and QLD state public health units where  
119 they were the first case identified in the household according to public health investigations and contact tracing.  
120 We recruited co-primary index cases where two household members tested positive within a 24-hour period and  
121 there was at least one other household member who was PCR-negative at baseline. In addition, we enriched for  
122 index paediatric cases by recruiting from the Royal Children's Hospital Respiratory Infection Clinic (RCH) in  
123 VIC. Recruitment was active between April–October 2020, prior to the emergence of any variants of concern  
124 (Supplementary Figures 1–4).

125 Households were defined as two or more people living together in a domestic residence or a dwelling or group  
126 of dwellings with a shared space. Residential institutions were not included. All locally acquired cases were  
127 eligible for recruitment regardless of local source of infection provided they lived within an appropriate  
128 geographical area for logistics (i.e., metropolitan areas), and were not in mandated 14-day quarantine. All  
129 household members of eligible cases were required to provide their consent to participate. Hospitalised index  
130 cases were eligible for recruitment as we assumed that household contacts were exposed by the time  
131 hospitalisation of the index case has occurred. Households were excluded when all household members were  
132 infected at the time of the initial visit, making the direction of transmission events unclear and unobservable.

133

134 Epidemiological data were collected from confirmed cases and household contacts as close as possible to  
135 laboratory confirmation (day 0/baseline) of the index case, including health status interviews on days 7,14 and  
136 where available day 28. The questionnaires collected details on participant demographics, symptoms and

137 vaccine and medical history (details provided in Supplementary Table 2). Household contacts also completed  
138 daily symptom diaries (via SMS) and provided specimens in line with Public Health Laboratory Network advice  
139 at baseline, days 7,14 and where available day 28. Respiratory swabs were professionally or self-collected  
140 depending on study site and were tested by polymerase chain reaction (PCR) in the state of collection.<sup>12</sup>  
141 Households were cleared from the project at day 14 if all household contacts were symptom free and tested  
142 negative for COVID-19 at previous study timepoints (baseline and days 7/14). Index/primary cases did not  
143 complete symptom diaries or provide further swabs during their involvement in the study.

144  
145 Deidentified data were collected and managed using REDCap electronic data capture tools hosted at The  
146 University of Melbourne. Ethics approval was not required for the FFX public health components being led  
147 through state and territory health departments as the project was recognised as an enhanced national public  
148 health surveillance activity. Ethics approval for the FFX project at the RCH site was obtained through the  
149 Murdoch Children’s Research Institute Ethics Committee (ref: 63666).

150

## 151 **Analysis**

152 Descriptive analyses were performed to explore the characteristics of initially confirmed cases and their  
153 household contacts.

154 The household secondary attack rate (HSAR) was defined as the proportion of household contacts that were  
155 eventually infected in their study follow-up. We assumed that individuals tested positive for COVID-19 by PCR  
156 if and only if they had COVID-19 (i.e., the false positive rate is zero) and infected household contacts had at  
157 least one positive PCR test during their follow-up period. We classified all further detected cases within  
158 households as secondary cases and assumed that the primary case was the source of infection.

159 We characterised and modelled disease spread within households using an SEIR-type compartmental  
160 mathematical model previously developed for pandemic influenza<sup>13-15</sup>, and adapted it for COVID-19 according  
161 to early evidence about the incubation period and the generation interval.<sup>16</sup> The model allows for pre- and  
162 asymptomatic infection status, and is age-structured allowing for age-specific contact rates.<sup>17</sup> Adults were  
163 defined as 18 years old or older, and children were defined as less than 18 years old. The rate of transmission  
164 was allowed to scale depending on the household size. Model parameters were estimated using a bespoke  
165 Markov chain Monte Carlo method<sup>15-16</sup>; additional model details are outlined in the Supplementary Technical  
166 Appendix. Median posterior estimates and 95% credible intervals (CrI) are reported.

167

168 Statistical analysis was also conducted to support the choice of variables considered in the mathematical model,  
169 identify other variables that may be able to inform the mathematical model, and to align with global FFX and  
170 UNITY studies. We used logistic regression models to investigate the association between the HSAR and case-  
171 and household-level covariates. Multilevel mixed-effects logistic regression models were used to account for  
172 multiple observations per household in the contact-level HSAR analysis. The covariates used in these models  
173 are detailed in Supplementary Table 3. Households with co-primary cases were excluded from the statistical  
174 HSAR analysis but are included in the household model analysis.

175

176 Alpha was set to 0.05, and covariates that had a p-value of  $<0.2$  in univariate regression analysis were included  
177 in the multivariable models for the different variable levels. Adjusted odds ratios, adjusted marginal estimates of  
178 the HSAR, and associated 95% confidence intervals (95% CIs) were produced for each included covariate.

179

180 Data cleaning and descriptive analyses were performed in R, (<https://www.r-project.org/>).<sup>18</sup> Statistical HSAR  
181 analyses were performed in Stata version 16.0 (StataCorp LLC, College Station, Texas).<sup>19</sup> All modelling and  
182 parameter estimation was performed using Julia 1.6.0 (<https://julialang.org/>).<sup>20</sup>



183 **Results**

184

185 **Characteristics of FFX study population**

186

187 We recruited 96 households with 101 confirmed index cases (due to co-primary cases) and 286 associated  
 188 household contacts between April 2020 and October 2020. Three households had a false positive index case and  
 189 were subsequently removed. Four households had incomplete study data. Supplementary Figure 1 shows  
 190 recruitment into our study over time in relation to the number of locally acquired cases in Australia and in states  
 191 that contributed data (Supplementary Figures 2–4).

192

193 FFX cases had a median age of 29 years (Interquartile range 15–42) and there were slightly more female cases  
 194 than males. Thirty-five of the confirmed cases were children (<18 years old). Further case and contact  
 195 participant characteristics can be seen in Table 1. The median household size was 4 (IQR 3–5) and ranged from  
 196 2–10 persons (Supplementary Figure 5).

197

198 **Table 1:** Characteristics of included case and household contact participants in the FFX project

199

	<b>Confirmed cases (n = 101, from 96 households)</b>	<b>Household contacts (n = 286)</b>
<b><i>Age, years</i></b>		
Mean (SD)	28.0 (18.3)	28.0 (19.3)
Median (IQR)	29.0 (15.0–42.0)	26.0 (11.0–44.0)
<b><i>Age group, No. (%)</i></b>		
<12	21.0 (20.8)	73.0 (25.5)
12-17	14.0 (13.9)	40.0 (14.0)
18-49	55.0 (54.5)	122.0 (42.7)
50+	11.0 (10.9)	51.0 (17.8)
<b><i>Sex, No. (%)</i></b>		
Male	48.0 (47.5)	141.0 (49.5)
Female	53.0 (52.5)	144.0 (50.5)
Other	0 (0)	0 (0)
<b><i>Received influenza vaccination in previous 12 months, No. (%)</i></b>		
Yes	55.0 (54.5)	131.0 (46.0)
No	45.0 (44.6)	151.0 (53.0)
Unknown	1.0 (1.0)	3.0 (1.0)
<b><i>Ever had pneumococcal vaccine, No. (%)</i></b>		
Yes	21.0 (20.8)	82.0 (28.8)
No	62.0 (61.4)	145.0 (50.9)
Unknown	18.0 (17.8)	58.0 (20.4)
<b><i>Pre-existing health conditions, No. (%)</i></b>		
Has pre-existing health conditions	27.0 (26.7)	87.0 (30.5)
Has no pre-existing health conditions	74.0 (73.3)	198.0 (69.5)
Asthma	8.0 (7.9)	32.0 (11.2)
Chronic respiratory condition (excluding asthma)	1.0 (1.0)	0 (0)

Cardiac disease	1·0 (1·0)	4·0 (1·4)
Immunosuppressive condition/therapy	0 (0)	1·0 (0·4)
Diabetes	3·0 (3·0)	8·0 (2·8)
Obese	1·0 (1·0)	5·0 (1·8)
Renal disease	1·0 (1·0)	1·0 (0·4)
Other condition(s)	14·0 (13·9)	41·0 (14·4)

200

201 Abbreviations:


202 IQR = Interquartile range

203

## 204 Household transmission dynamics – mathematical modelling

205

206 Of the 286 household contacts recruited into the study, 40 tested positive for SARS-CoV-2 by PCR, with the  
 207 majority (36/40, 90%) being detected and confirmed by the Day 7 timepoint. The modelling analysis is based on  
 208 households with sufficient data (92 households comprising of 230 adults and 140 children). Of the included  
 209 households, 68 had a single case only and experienced no secondary transmission. Final size distributions (i.e.,  
 210 the total number of individuals with laboratory-confirmed infections within a household over the period of  
 211 monitoring) are shown in Figure 1.




212

213 **Figure 1:** Final size distributions for the 92 households, where N is the size of the household. A final size of 1  
 214 indicates no secondary infections. There are no households of size 9 in the dataset.

215 Posterior distributions for the household secondary attack rate (HSAR) unstratified and stratified by household  
 216 size, N (HSAR<sub>N</sub>), are shown in Figure 3. In both panels of this figure, HSAR is calculated as an average over  
 217 the households in the dataset to account for the age-structured mixing and difference in adult-child

218 transmissibility/susceptibility. The HSAR was estimated to be 15% (95%CrI 8–25%, Figure 2a) which increases  
219 with household size (Figure 2b).  
220



221


222

223 **Figure 2:** Posterior distributions for (A) the household secondary attack rate (HSAR) and (B) the household  
224 secondary attack rate conditional on household size  $N$  ( $HSAR_N$ ) shown in blue. The grey curve shows the prior  
225 distribution. In (B) the dots represent the median of the distributions.  $HSAR$  and  $HSAR_N$  are calculated as  
226 averages over the households in the study and over all ages.

227

228 Adults had a higher likelihood of showing symptoms than children (Supplementary Figure 8). Children were  
229 found to be more susceptible than adults – the median posterior estimate of the relative susceptibility of children  
230 compared to adults was 1.26 (95%CrI 0.75–2.08) as seen in Figure 3A. Children were also less infectious than  
231 their adult counterparts – the median posterior estimate of relative transmissibility compared to adults was 0.52  
232 (95%CrI 0.23–1.06), as seen in Figure 3B.

233



234

235

236 **Figure 3:** Posterior distributions (blue lines) for the relative susceptibility (A) and transmissibility (B) from  
237 children compared to adults, shown in blue. Prior distributions are shown in grey.

238

### 239 **Household transmission dynamics – statistical analysis**

240

241 Using the contact-level mixed-effects logistic regression model and excluding households with co-primary  
242 cases, the HSAR estimate was found to be 12% (95% CI 7–17%). Details of the multivariable logistic regression  
243 models at the various factor-levels are presented in Supplementary Table 4. The odds ratio estimate for  
244 household size was 1.31 (95% CI 0.97–1.77,  $p=0.080$ ), representing an average 31% increase in the odds of  
245 secondary infection within the household for each one person increase in household size. There is some  
246 evidence to suggest that HSAR is associated with the relationship between cases and their contacts –  
247 parents/guardians/carers and siblings had lower odds of being a secondary case when children were the primary  
248 case. The other covariates included in the multivariable models were not found to be associated with the HSAR.

249

### 250 **Severity**

251

252 Four confirmed cases were hospitalised during their follow-up period (Case hospitalisation rate, 2.8% (4/141),  
253 95% CI 0.9–7.5%) and no deaths were reported in our cohort.

254

255 Overall, 31.9% (45/141) of confirmed cases were asymptomatic (95% CI 24–40%). 10/101 (9.9%) were  
256 asymptomatic primary cases at baseline and 35/40 (87.5%) secondary cases were asymptomatic during their  
257 follow-up. Symptoms experienced by household contacts by COVID-19 status can be seen in Supplementary  
258 Figure 6.

259

## 260 **Discussion**

261

262 Our household transmission study estimates the HSAR in Australia to be 15% (95%CrI 8–25%) prior to the  
263 emergence of variants of concern. We demonstrate that the HSAR increases with household size. Children were  
264 relatively more susceptible to infection compared to adults when exposed and were also less infectious than  
265 their adult counterparts.

266

267 The ‘gold-standard’ mathematical model captures the complex timing and dynamics of transmission in  
268 households. Thus, we believe these results to be more robust than those produced by the statistical models.  
269 Associations in the statistical modelling need to be taken with caution due to the small sample size and our  
270 underlying assumption that all cases we observe in our households are attributed to the primary case – an  
271 assumption that is not required in the mathematical model. However, the statistical model results are important  
272 as they are broadly consistent with the results from the robust mathematical modelling approach, and represent  
273 the standard analytic method that is used to analyse such household transmission studies. They are presented  
274 here such that results from our cohort may be fairly compared to other international studies.

275

276 Our HSAR estimate is consistent with estimates from two systematic review and meta-analyses of household  
277 transmission.<sup>21,22</sup> We note that our results differ from similar household transmission studies including studies  
278 based on the WHO UNITY protocols, such as the FFX study conducted in the UK, which estimated a higher  
279 base HSAR that decreased with increasing household size.<sup>23-33</sup> Other studies using population surveillance data,  
280 which represent transmission within a broader range of settings than the household, have estimated lower  
281 relative susceptibility to SARS-CoV-2 infection for children compared to adults.<sup>34,35</sup>

282

283 It can be difficult to make direct comparisons between studies that are conducted in different countries and  
284 settings due to the unique features of local epidemics and adaptations required for implementation. Studies  
285 should be interpreted in light of the local epidemiology and context – considerations should be made for the  
286 surveillance and contact tracing capacity, local incidence of COVID-19 cases during study implementation,  
287 predominant circulating SARS-CoV-2 variant, the timing and duration of the study, and study design including  
288 case ascertainment strategies and specimen sampling methods. Characteristics of individuals affected by  
289 COVID-19 and recruited into the study such as socioeconomic status, occupation and size of recruited  
290 households may also be significantly different across these studies, and therefore may influence aggregate

291 outcomes. Additionally, differences in public health interventions such as: test, trace and isolate capacity and  
292 practices; behavioural and distancing measures; mobility restrictions; communication campaigns; and varying  
293 degrees of community engagement and cohesion in response, could also help to explain how estimates may vary  
294 across countries and settings.

295

296 We note ascertainment and recruitment bias in our study cohort that may contribute to some of the differences  
297 we observe to other studies – we excluded households where all members of these households were already  
298 infected at baseline. This was more likely to exclude smaller households than larger households for  
299 participation, and subsequently may have resulted in the HSAR for smaller households being underestimated.  
300 Our modelling outputs are therefore influenced more strongly by larger households, particularly three large  
301 outbreaks in households with more than five household members. These may be outliers and as such the  
302 observed effect could disappear if more data had been collected including from smaller households who  
303 experienced rapid transmission making them ineligible for recruitment. Additional sources of data could help us  
304 understand the extent to which our results are influenced by our inherent study biases and if our HSAR estimate  
305 is an underestimate, or if it is rather a feature of Australia’s unique epidemiology, i.e. transmission in a low  
306 incidence setting with stringent public health and social measures to reduce within-household and community  
307 transmission.

308

309 We did not observe longer chains of infection in households that had detected secondary transmission. As a  
310 result, there were insufficient data to confidently estimate other quantities of interest such as the incubation  
311 period, and the pre-symptomatic and symptomatic infectious periods. Although some households experienced  
312 larger absolute numbers of cases, in the majority of such households most individuals were already infected at  
313 the recruitment baseline or initial swabbing time point (90% of secondary cases were positive by day 7 testing).  
314 These outcomes were expected especially as public health units provided extensive advice to reduce the  
315 probability of additional spread within the household, including advice on mask use, and how to isolate from  
316 each other in their homes. Whilst not the case in this cohort, some cases were removed from their household to  
317 further mitigate the risk of spread if their home environment was not suitable for quarantine.

318

319 We conducted sensitivity analyses to consider how the arbitrary age cut-off of 18 years to define adults and  
320 children and the use of our contact matrices were impacting our results. We explored age cut-offs of 8,13 and 16  
321 years of age. We found that the estimated HSAR was not sensitive to changes in the age cut-off (Supplementary

322 Figure 8). There are small differences in the probability of symptom onset for the different age cut-offs  
323 (Supplementary Figure 9), although these appear to be centred on the same values. The age cut-off of 16 yielded  
324 posterior estimates for the probability of symptom onset that were very similar. There was no sensitivity to the  
325 contact matrix being used – this is likely a result of the large number of households who experienced no  
326 secondary transmission.

327

328 Our study has several strengths: This is the first multi-jurisdictional household transmission study of its kind for  
329 SARS-CoV-2 in Australia. We provide insights into household transmission with testing of known household  
330 contacts regardless of symptoms in a sustained low incidence setting, where there is more certainty about the  
331 source of SARS-CoV-2 transmission being from within the household, rather than the community, compared to  
332 a higher incidence setting. The pre-existing relationship between public health departments and APPRISE  
333 researchers was an enabling factor to provide capacity for the implementation of the study, as Australian health  
334 departments were prioritising hospital preparedness and scaling up testing and contact tracing in early 2020  
335 when this study commenced. Our study enriched for paediatric cases through recruitment at the RCH site –  
336 children were generally not index cases at the other sites, and as such this recruitment strategy provided us with  
337 unique insights into household transmission from children in the Australian context.

338

339 Operationally, our data fields were aligned with the National Notifiable Diseases Surveillance Scheme to  
340 harmonise with enhanced surveillance efforts and reduce duplication of data collection where possible. Our  
341 bespoke REDCap database provided a central repository to analyse FFX data as a national dataset. Analysis and  
342 reporting of FFX data was performed in real time to key national and international stakeholders including, the  
343 Communicable Diseases Network Australia (CDNA), WHO Headquarters and the WHO Western Pacific  
344 Regional Office.

345

346 The lack of an Australian specific protocol with a pre-determined implementation strategy led to issues with  
347 logistics, and made it difficult to obtain the relevant ethics and governance approvals for all associated research  
348 components. We originally anticipated a 6–8 week window of intense recruitment in line with a short and sharp  
349 epidemic in early 2020. Strong social and public health control measures including border closures and  
350 mandated hotel quarantine reduced case numbers and subsequently the number of eligible cases and households.  
351 Two of our sites (QLD and SA) had sustained zero community transmission of COVID-19 by the time they  
352 were ready to recruit in April 2020 and WA achieved this in May 2020 after only recruiting four households.

353 We were able to recruit more as epidemic activity increased in VIC and NSW in mid-2020, but case  
354 ascertainment in Victoria was limited due to recruitment being limited to the paediatric hospital site. These  
355 factors prolonged the duration of our study and may have further contributed to our ascertainment bias.

356 Future research will also involve further collection and analysis of associated genomic and serological data in  
357 the FFX research components to better understand and confirm the transmission dynamics in our cohort.  
358 Genomic data can help confirm our classification of individuals as we assumed additional cases in the  
359 household were attributed to the index case. Serological data may identify historic infections in individuals who  
360 continue to present as PCR positive but are non-infectious. Serological data may also be important to identify  
361 previously undetected infections in household members especially as the rate of false negatives from PCR may  
362 not be insignificant.<sup>36</sup> Together these can provide more accurate data to classify household members and  
363 subsequently inform attack rate calculations.

364 Our study provides important baseline data characterising the transmission of early SARS-CoV-2 strains from  
365 children and adults in the Australian context, against which properties of emerging variants of concern such as  
366 the Alpha and Delta strains can be benchmarked.<sup>37-40</sup> We plan to follow our recruited FFX households  
367 longitudinally to continue to develop our understanding of household transmission and immunity in the context  
368 of emerging variants of concern. This study will be conducted as Australia's vaccination program continues and  
369 throughout the eventual establishment of community transmission of SARS-CoV-2 in Australia. Research is  
370 also currently underway to formally evaluate the implementation of our FFX study to help consolidate on  
371 lessons learnt and inform preparedness efforts for future FFX studies in Australia for COVID-19 or other  
372 infectious disease emergencies.

373

## 374 **Conclusion**

375

376 The Australian FFX project for COVID-19 has been useful to provide valuable insight into the epidemiology of  
377 SARS-CoV-2 in Australia despite encountering many challenges in the planning and implementation phases  
378 with respect to logistics, ethics, governance and data management. Continued efforts to invest in preparedness  
379 research will help to test, refine and further develop Australian FFX study protocols in advance of future  
380 outbreaks of concern and ensure they are embedded in pandemic response plans.<sup>41,42</sup> Being able to rapidly  
381 activate and provide high-quality information in real-time will be useful for epidemic situational assessment and



382 modelling studies in response to future outbreaks of concern, to ensure a more proportionate, equitable and  
383 targeted public health response and help reduce disease impact.

384

385 **Funding Sources:**

386

387 The public health components of the Australian FFX Household Transmission Project were funded by the  
388 Australian Government Department of Health.

389

390 **Acknowledgements:**

391

392 The Australian FFX Household Transmission Project Group (alphabetical order): Ross Andrews, Laura  
393 Bannerman, Christina Bareja, Andrew Black, Douglas Boyle, Georgina Collins, Jo Collins, Loral Courtney,  
394 Nigel Crawford, Katina D’Onise, Lucy Deng, Kate Dohle, Andrew Dunn, Paul Effler, James Fielding, Erin  
395 Flynn, Rob Hall, Sonia Harmen, Troy Laidlow, Eileen Lam, Adrian Marcato, Jodie McVernon, Niamh  
396 Meagher, Adriana Milazzo, Caroline Miller, Dylan Morris, Janette Mulvey, Sera Ngeh, Genevieve O’Neill,  
397 Kate Pennington, Priyanka Pillai, Ben Polkinghorne, David Price, Victoria Pye, Joshua Ross, Freya Shearer,  
398 Miranda Smith, Paula Spokes, Andrew Steer, Mark Taylor, Shidan Tosif, Florian Vogt, James Walker, Nicholas  
399 Wood.

400

401 The Communicable Diseases Network Australia, for their input in the planning stages of the project, oversight  
402 and review of the article.

403

404 **References:**

- 405 1 World Health Organization. WHO Director-General's opening remarks at the media briefing on  
406 COVID-19 - 11 March 2020 [Internet]; 2020 ([https://www.who.int/director-](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)  
407 [general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)  
408 [11-march-2020](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020), accessed 6<sup>th</sup> December 2021)
- 409
- 410 2 World Health Organization, Global Research on coronavirus disease (COVID-19); 2021  
411 ([https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov)  
412 [coronavirus-2019-ncov](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov) , accessed 6th December 2021)
- 413
- 414 3 World Health Organization, The first few X cases and contacts (FFX) investigation protocol for  
415 coronavirus disease 2019 (COVID-19), version 2.2; 2021 ([https://www.who.int/publications/i/item/the-](https://www.who.int/publications/i/item/the-first-few-x-cases-and-contacts-(ffx)-investigation-protocol-for-coronavirus-disease-2019-(covid-19)-version-2.2)  
416 [first-few-x-cases-and-contacts-\(ffx\)-investigation-protocol-for-coronavirus-disease-2019-\(covid-19\)-](https://www.who.int/publications/i/item/the-first-few-x-cases-and-contacts-(ffx)-investigation-protocol-for-coronavirus-disease-2019-(covid-19)-version-2.2)  
417 [version-2.2](https://www.who.int/publications/i/item/the-first-few-x-cases-and-contacts-(ffx)-investigation-protocol-for-coronavirus-disease-2019-(covid-19)-version-2.2) , accessed 6th December 2021)
- 418
- 419 4 Marcato AJ, Fielding J, Crooks K et al. The ongoing value of First Few X studies for COVID-19 in the  
420 Western Pacific Region. In press article.
- 421
- 422 5 World Health Organization, Coronavirus disease (COVID-19) technical guidance: The Unity Studies:  
423 Early Investigation Protocols; 2021 ( [https://www.who.int/emergencies/diseases/novel-coronavirus-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigations)  
424 [2019/technical-guidance/early-investigations](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigations) , accessed 6th December 2021)
- 425
- 426 6 Bergeri I, Lewis HC, Subissi L et al. Early epidemiological investigations: World Health Organization  
427 UNITY protocols provide a standardized and timely international investigation framework during the  
428 COVID-19 pandemic. *Influenza Other Respir Viruses*. 2021 [Epub ahead of print].  
429 doi:10.1111/irv.12915 pmid:34611986
- 430
- 431 7 The Australian Partnership for Preparedness Research on Infectious Disease emergencies, 2021 (  
432 <https://www.apprise.org.au/> , accessed 6<sup>th</sup> December 2021)
- 433

- 434 8 The Australian Partnership for Preparedness Research on Infectious Disease emergencies. First Few X'  
435 (FFX) research project to enhance the public health response to COVID-19 in Australia. 2021,  
436 ([https://www.apprise.org.au/project/first-few-x-ffx-research-project-to-enhance-the-public-health-](https://www.apprise.org.au/project/first-few-x-ffx-research-project-to-enhance-the-public-health-response-to-covid-19-in-australia/)  
437 [response-to-covid-19-in-australia/](https://www.apprise.org.au/project/first-few-x-ffx-research-project-to-enhance-the-public-health-response-to-covid-19-in-australia/) , accessed 6<sup>th</sup> December 2021)  
438
- 439 9 Australian Government Department of Health, Australian Health Protection Principal Committee  
440 (AHPPC) statement on strategic direction, 2020; ([https://www.health.gov.au/news/australian-health-](https://www.health.gov.au/news/australian-health-protection-principal-committee-ahppc-statement-on-strategic-direction)  
441 [protection-principal-committee-ahppc-statement-on-strategic-direction](https://www.health.gov.au/news/australian-health-protection-principal-committee-ahppc-statement-on-strategic-direction), accessed 6th December 2021)  
442
- 443 10 Australian Government Department of Health, Coronavirus (COVID-19) current situation and case  
444 numbers, 2021; [https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-](https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-current-situation-and-case-numbers)  
445 [alert/coronavirus-covid-19-current-situation-and-case-numbers](https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-current-situation-and-case-numbers) , accessed 6<sup>th</sup> December 2021)  
446
- 447 11 COVID-19 National Incident Room Surveillance Team (2021). COVID-19 Australia: Epidemiology  
448 Report 55 Reporting period ending 21 November 2021. *Communicable diseases intelligence*  
449 (2018), 45, 10.33321/cdi.2021.45.65. <https://doi.org/10.33321/cdi.2021.45.65>  
450
- 451 12 Australian Government Department of Health, Public Health Laboratory Network Publications, 2021  
452 (<https://www1.health.gov.au/internet/main/publishing.nsf/Content/Publications-13> , accessed 6th  
453 December 2021)  
454
- 455 13 Black AJ, Geard N, McCaw JM, McVernon J, Ross JV. Characterising pandemic severity and  
456 transmissibility from data collected during first few hundred studies. *Epidemics*. 2017;19:61-73.  
457
- 458 14 Black, AJ. Importance sampling for partially observed temporal epidemic models. *Statistics and*  
459 *Computing*, 2019, 29, 617-630  
460
- 461 15 Walker JN, Black AJ, Ross JV. Bayesian model discrimination for partially-observed epidemic models.  
462 *Math Biosci*. 2019;317:108266.  
463

- 464 16 Lauer SA, Grantz KH, Bi Q et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19)  
465 From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med.*  
466 2020;172(9):577-82.  
467
- 468 17 Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using contact surveys and  
469 demographic data. *PLOS Computational Biology.* 2017;13(9):e1005697.  
470
- 471 18 R Core Team (2021). R: A language and environment for statistical computing. R Foundation for  
472 Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>  
473
- 474 19 StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC.  
475
- 476 20 Julia: A Fresh Approach to Numerical Computing. Jeff Bezanson, Alan Edelman, Stefan Karpinski,  
477 Viral B. Shah. (2017) *SIAM Review*, 59: 65–98. doi: 10.1137/141000671.pdf.  
478
- 479 21 Madewell ZJ, Yang Y, Longini IM, Jr, Halloran ME, Dean NE. Household Transmission of SARS-  
480 CoV-2: A Systematic Review and Meta-analysis. *JAMA Network Open.* 2020;3(12):e2031756-e.  
481
- 482 22 Thompson HA, Mousa A, Dighe A et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-  
483 CoV-2) Setting-specific Transmission Rates: A Systematic Review and Meta-analysis. *Clinical*  
484 *Infectious Diseases.* 2021;73(3):e754-e64.  
485
- 486 23 House T, Pellis L, Pouwels KB et al., Inferring Risks of Coronavirus Transmission from Community  
487 Household Data. Preprint. arXiv. 2021; <https://arxiv.org/abs/2104.04605>  
488
- 489 24 Dattner I, Goldberg Y, Katriel G et al. The role of children in the spread of COVID-19: Using  
490 household data from Bnei Brak, Israel, to estimate the relative susceptibility and infectivity of children.  
491 *PLOS Computational Biology.* 2021;17(2):e1008559.  
492

- 493 25 Li F, Li Y-Y, Liu M-J et al. Household transmission of SARS-CoV-2 and risk factors for susceptibility  
494 and infectivity in Wuhan: a retrospective observational study. *The Lancet Infectious Diseases*.  
495 2021;21(5):617-28.  
496
- 497 26 Pung R, Park M, Cook AR, Lee VJ. Age-related risk of household transmission of COVID-19 in  
498 Singapore. *Influenza Other Respir Viruses*. 2021;15(2):206-8.  
499
- 500 27 Reukers DFM, van Boven M, Meijer A, et al. High infection secondary attack rates of SARS-CoV-2 in  
501 Dutch households revealed by dense sampling. *Clinical Infectious Diseases*. 2021.  
502
- 503 28 Cerami C, Popkin-Hall ZR, Rapp T et al. Household transmission of SARS-CoV-2 in the United  
504 States: living density, viral load, and disproportionate impact on communities of color. *Clin Infect Dis*.  
505 2021.  
506
- 507 29 Lewis NM, Chu VT, Ye D et al. Household Transmission of SARS-CoV-2 in the United States. *Clin*  
508 *Infect Dis*. 2020.  
509
- 510 30 Ng OT, Marimuthu K, Koh V et al. SARS-CoV-2 seroprevalence and transmission risk factors among  
511 high-risk close contacts: a retrospective cohort study. *The Lancet Infectious Diseases*. 2021;21(3):333-  
512 43.  
513
- 514 31 Ratovoson R, Razafimahatratra R, Randriamanantsoa L et al. Household transmission of COVID-19  
515 among the earliest cases in Antananarivo, Madagascar. *Influenza Other Respir Viruses*. 2021.  
516
- 517 32 Bernal JL, Panagiotopoulos N, Byers C et al. Transmission dynamics of COVID-19 in household and  
518 community settings in the United Kingdom. *medRxiv*. 2020:2020.08.19.20177188.  
519
- 520 33 Miller E, Waight PA, Andrews NJ et al. Transmission of SARS-CoV-2 in the household setting: A  
521 prospective cohort study in children and adults in England. *J Infect*. 2021.  
522

- 523 34 Viner RM, Mytton OT, Bonell C et al. Susceptibility to SARS-CoV-2 Infection Among Children and  
524 Adolescents Compared With Adults: A Systematic Review and Meta-analysis. *JAMA Pediatrics*.  
525 2021;175(2):143-56.  
526
- 527 35 Davies NG, Klepac P, Liu Y et al. Age-dependent effects in the transmission and control of COVID-19  
528 epidemics. *Nature Medicine*. 2020;26(8):1205-11.  
529
- 530 36 Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative Rate of  
531 Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure.  
532 *Ann Intern Med*. 2020;173(4):262-7.  
533
- 534 37 Davies NG, Abbott S, Barnard RC et al. Estimated transmissibility and impact of SARS-CoV-2 lineage  
535 B.1.1.7 in England. *Science*. 2021;372(6538):eabg3055.  
536
- 537 38 Wibmer CK, Ayres F, Hermanus T et al. SARS-CoV-2 501Y.V2 escapes neutralization by South  
538 African COVID-19 donor plasma. *bioRxiv*. 2021:2021.01.18.427166.  
539
- 540 39 Naveca F, Nascimento V, Souza V et al. COVID-19 epidemic in the Brazilian state of Amazonas was  
541 driven by long-term persistence of endemic SARS-CoV-2 lineages and the recent emergence of the  
542 new Variant of Concern P.1, 25 February 2021, PREPRINT (Version 1) available at Research Square  
543 [<https://doi.org/10.21203/rs.3.rs-275494/v1>]  
544
- 545 40 Public Health England, SARS-CoV-2 variants of concern and variants under investigation in England,  
546 Technical briefing 11; 2021 ([https://www.gov.uk/government/publications/investigation-of-novel-sars-](https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201)  
547 [cov-2-variant-variant-of-concern-20201201](https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201), accessed 6th December 2021)  
548
- 549 41 Australian Health Sector Emergency Response Plan for Novel Coronavirus (COVID-19) ; 2020  
550 ([https://www.health.gov.au/resources/publications/australian-health-sector-emergency-response-plan-](https://www.health.gov.au/resources/publications/australian-health-sector-emergency-response-plan-for-novel-coronavirus-covid-19)  
551 [for-novel-coronavirus-covid-19](https://www.health.gov.au/resources/publications/australian-health-sector-emergency-response-plan-for-novel-coronavirus-covid-19) , accessed 6th December 2021)  
552

553           42 Australian Government Department of Health. Australian Health Management Plan for Pandemic  
554           Influenza; 2014 (<https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-ahmppti.htm> ,  
555           accessed 6<sup>th</sup> December 2021)  
556

557 **Supplementary Appendix**

	Summary	Funding source
<i>Public health component</i>	<ul style="list-style-type: none"> <li>- Data collection from confirmed cases as close as possible to laboratory confirmation including status interviews on days 7,14 ± 28</li> <li>- Data collection from household contacts including daily symptom diaries and status interviews on days 7,14, ± 28</li> <li>- Specimens at days 0,7,14 ± 28 from household contacts. Professionally collected or self-collected depending on site, in line with the Australian Public Health Laboratory Network advice</li> <li>- Households to end participation where the entire household is symptom and COVID-19 free at the day 14 time point</li> </ul>	Australian Commonwealth Department of Health
<i>Research component 1 – components of protocol not deemed to be essential public health activity in February 2020</i>	<ul style="list-style-type: none"> <li>- Sequencing of previously collected positive specimens in the public health project</li> <li>- Collection of blood sample from household contacts after any self-isolation/quarantine periods have been served</li> </ul>	APPRISE Centre of Research Excellence
<i>Research component 2 – extended follow-up of FFX cohort over 3 year period</i>	<ul style="list-style-type: none"> <li>- Repeat serology from current recruits</li> <li>- Ongoing FFX recruitment – trialling FluTracking arm and Aboriginal Community Controlled Health Organisation led First Nations pilot study</li> </ul>	Australian National Health and Medical Research Council (partnership grant in collaboration with the Australian Commonwealth Department of Health and Hunter New England Local Health District)

558 **Supplementary Table 1:** Australian FFX Household Transmission Project Components and details

559

560 **Supplementary Table 2:** Data collected in the Australian FFX questionnaires

Case data	Contact data
<ul style="list-style-type: none"> <li>- Demographic data; age, sex, pregnancy</li> <li>- Aboriginal and Torres Strait Islander status</li> <li>- Household demographics; household size and number of bedrooms, postcode</li> <li>- Symptom data (including symptom diaries where relevant)</li> <li>- Comorbidity data</li> <li>- Laboratory data (swabs)</li> <li>- Influenza/pneumococcal vaccination data</li> <li>- Follow up data; including hospitalisation status at study time points</li> </ul>	<ul style="list-style-type: none"> <li>- Demographic data; age, sex, pregnancy</li> <li>- Aboriginal and Torres Strait Islander status</li> <li>- Relationship to case, and extent of contact</li> <li>- Symptom data (including symptom diaries)</li> <li>- Comorbidity data</li> <li>- Laboratory data (swabs)</li> <li>- Influenza/pneumococcal vaccination data</li> <li>- Follow up data; including hospitalisation status at study time points</li> </ul>

561

562



563 **Supplementary Table 3:** Covariates explored in the univariate and multivariable logistic and negative binomial  
 564 regression models  
 565

Case covariates	<ul style="list-style-type: none"> <li>- Number of respiratory symptoms experienced by the case (fever, cough, sore throat, shortness of breath, loss of taste, loss of smell, runny nose)</li> <li>- Does the case have conditions that may affect ability to transmit onwards or not (asthma, chronic respiratory disease, immunosuppression)</li> <li>- Time between date of symptom onset and date of baseline test as a proxy for time before PHU intervention</li> <li>- Gender of primary case</li> <li>- Hospitalisation of the case</li> </ul>
Household covariates	<ul style="list-style-type: none"> <li>- Household size (for direct comparison to the mathematical model)</li> <li>- Household density – proxy calculated as HH size divided by the number of bedrooms in the household</li> <li>- Composition of household – family (parent/s and children), share-house, complex (multigenerational family or other)</li> <li>- Number of children (&lt;18 years) in household</li> </ul>
Contact covariates	<ul style="list-style-type: none"> <li>- Gender of contacts</li> <li>- Relationship to case</li> <li>- Number of measured contact events at baseline (include sharing of spaces, facilities, bedroom)</li> <li>- Time between the case baseline test and first contact test as a proxy for time before PHU intervention</li> <li>- Number of pre-existing conditions (asthma, chronic respiratory condition, cardiac disease, immunosuppressive condition/therapy, diabetes, obesity, liver disease, renal disease, neurological disorder)</li> </ul>

566

567

568 **Supplementary Table 4:** Results from the multivariable logistic regression models of HSAR. Covariates were  
 569 included in the multivariable logistic regression models if they had a p-value of <0.2 in univariate regression  
 570 analysis. The estimates presented here are exclusive of households with co-primary cases.

571

Covariate	Variable level	Adjusted odds ratio (95% CI)	p-value	Adjusted HSAR estimate (95% CI)
<i>Household-level model (n=91)</i>				
<i>Household size<sup>#</sup></i>	2	Overall – 1.35 (0.99, 1.84)*	0.054*	0.11 (0.02, 0.21)*
	3			0.15 (0.07, 0.24)*
	4			0.20 (0.11, 0.28)*
	5			0.26 (0.15, 0.35)*
	6			0.33 (0.16, 0.46)*
	7			0.41 (0.16, 0.60)*
	8			0.49 (0.15, 0.75)*
	9			0.57 (0.15, 0.90)*
	10			0.65 (0.24, 0.96)*

<i>Case-level model (n=91)</i>				
<i>Ever hospitalised (from case-level model)</i>	No	Ref		0.21 (0.13, 0.30)
	Yes	2.56 (0.29, 22.34)	0.395	0.40 (0, 0.90)
<i>Number of transmitting conditions (asthma, chronic respiratory disease, immunosuppression)</i>	0	Ref		0.20 (0.11, 0.29)
	1	2.75 (0.61, 12.34)	0.186	0.40 (0.07, 0.74)
<i>Contact-level model (n=276)</i>				
<i>Multilevel mix effects logistic regression model, incorporating clustering by household</i>				
<i>Contact relationship to case</i>	Child	Ref	-	0.22 (0.10, 0.33)
	Other***	0.60 (0.01, 4.14)	0.271	0.08 (0, 0.23)
	Parent/guardian/carer	0.07 (0.01, 0.39)	<0.01	0.04 (0, 0.09)
	Partner/spouse	0.57 (0.15, 2.24)	0.422	0.16 (0.06, 0.27)
	Sibling	0.23 (0.04, 1.16)	0.074	0.1 (0.01, 0.17)
<i>Sex</i>	Female	Ref	-	0.10 (0.04, 0.14)
	Male	2.37 (0.80, 6.95)	0.117	0.14 (0.08, 0.20)
<i>Number of pre-existing conditions (as defined in Supplementary Table 3)</i>	0	Ref	-	0.10 (0.05, 0.14)
	1	6.37 (1.40, 28.89)	0.016	0.26 (0.10, 0.39)
	2	2.47 (0.10, 62.85)	0.585	0.16 (0, 0.42)

572

573 \* Results from the univariate regression models are presented where only one covariate was eligible to be

574 included in the multivariable model


575 \*\*\* Includes grandparents, grandchildren, partners of household contacts, housemates

576 # HH sizes were fit as a continuous variable and estimates presented for the range of household sizes in our study

577 population. We didn't have a household of size 9, and so we are extrapolating from the data that we have

578

579




580

581 **Supplementary Figure 1:** Recruitment into the Australian FFX project (bars) and confirmed cases across  
582 Australia (line). Note that the epidemic curve represents includes all cases reported in Australia from the  
583 commencement of the project (April 6<sup>th</sup> 2020), and not necessarily all eligible local cases for inclusion into the  
584 project.

585

586



587

588 **Supplementary Figure 2:** Recruitment into the Australian FFX project (bars) and confirmed cases in New  
 589 South Wales (line). Note that the epidemic curve represents includes all cases reported in New South Wales  
 590 from the commencement of the project (April 6<sup>th</sup> 2020), and not necessarily all eligible local cases for inclusion  
 591 into the project.

592

593

594

595

596

597

598


599

600

601

602

603



604

605 **Supplementary Figure 3:** Recruitment into the Australian FFX project (bars) and confirmed cases in Victoria  
606 (line). Note that the epidemic curve represents includes all cases reported in Victoria from the commencement  
607 of the project (April 6<sup>th</sup> 2020), and not necessarily all eligible local cases for inclusion into the project identified  
608 at the Royal Children’s Hospital.

609

610


611

612

613

614

615



616

617 **Supplementary Figure 4:** Recruitment into the Australian FFX project (bars) and confirmed cases at the

618 Western Australia (line). Note that the epidemic curve represents includes all cases reported in Western

619 Australia from the commencement of the project (April 6<sup>th</sup> 2020), and not necessarily all eligible local cases for

620 inclusion into the project.

621

622

623

624

625

626

627


628

629

630


631

632




633

634 **Supplementary Figure 5:** Histogram of recruited household sizes by state.



635

636 **Supplementary Figure 6:** Symptoms reported by household contacts during study follow-up.



637

638

639 **Supplementary Figure 7:** Prior distribution on the generation time implied by the prior distributions on the  
640 basic parameters discussed in the Supplementary Technical Appendix. The solid line represents the mean and  
641 the shaded region the 95% Credible Intervals.

642

643

644


645

646

647

648

649




650

651

652 **Supplementary Figure 8:** Posterior distributions for the household secondary attack rate using different age  
653 cut-offs to define children and adults (in years).

654





655

656

657

658 **Supplementary Figure 9:** Posterior distributions for the probability of displaying symptoms, conditional on

659 testing positive for adults (blue) and children (green) defined at various age cut-offs (in years). The grey curve

660 indicates the prior distribution.

661

#### 662 **Additional model details – modelling appendix**

663

664 Disease spread within a household was characterised using an SEIR-type compartmental mathematical model

665 previously developed for pandemic influenza<sup>1-3</sup>, adapted to COVID-19. The model allows for pre- and

666 asymptomatic infection status, and is age-structured with age-specific contact rates.<sup>4</sup> Adults were defined as 18

667 years old or older, and children were defined as less than 18 years old.

668

669 The structure of the model is illustrated in Appendix Figure 1 with associated parameters described in Appendix

670 Table 1. The classes are split into multiple, identical stages, which makes the distribution of time spent within

671 each class Erlang distributed (rather than exponential) to more accurately reflect the distribution time in each

672 period. The number of stages was chosen to reflect evidence about the distributions of the incubation period


673 and/or the generation interval.<sup>5</sup>

674

675 The rate of transmission scales depending on the household size,  $N$ , and the ages of individuals that they make  
 676 contact within a household. The transmission rate from an infectious adult of age  $n$  to a susceptible adult of age  
 677  $m$  is given by  
 678

$$\frac{\beta c_{n,m}}{(N-1)^\alpha}$$

679  
 680 where parameters are as described in Appendix Table 1. The infection rate is scaled based on an individual's age  
 681 – specifically, the rate of transmission from an adult to a child is multiplied by  $r_s$ , the rate of transmission from a  
 682 child to an adult is multiplied by  $r_t$ , and the rate of transmission from a child to another child is multiplied by  
 683  $r_s r_t$ . The terms  $r_s$  and  $r_t$  represent the relative susceptibility and transmissibility of children, respectively.



684  
 685  
 686 **Appendix Figure 1:** SEIR model structure for the spread of COVID-19 within a household. This illustrates the  
 687 epidemiological states an individual may be in and how they transition between these states. These states are: S  
 688 (susceptible);  $E_{1,2,3}$  (exposed);  $P_{1,2,3}$  (pre-symptomatic and infectious);  $I_{1,2}$  (infectious and symptomatic);  $I_{1a,2a}$   
 689 (infectious and asymptomatic), and; R (recovered). The red arrow indicates the transition when an individual  
 690 begins to show symptoms. At some point within the infectious period an individual may be hospitalised, and  
 691 hence removed from the household.

692  
 693 **Appendix Table 1:** Parameters for the model shown in Appendix Figure 1.

694

Parameter	Description
$N$	Size of household
$c_{n,m}$	Contact rate between age $n$ and $m$ individuals
$1/\sigma$	Average time spent in exposed states
$1/\lambda$	Average time spent in pre-symptomatic states
$1/\gamma$	Average time spent in states $I_1, I_2, I_{1a}$ and $I_{2a}$
$p_a$	Probability of developing symptoms for adults
$p_c$	Probability of developing symptoms for children
$\beta$	Rate of infection from adults to adults per contact in a

	household of size 2
$r_s$	Relative susceptibility of children
$r_t$	Relative transmission from children
$\alpha$	Household size transmission scaling term

695

696 Bayesian inference is performed targeting the parameters of the model using a custom Markov chain Monte  
 697 Carlo method. The likelihood is estimated using a particle filter that targets the final size of the outbreak within  
 698 a house, thus we ignore temporal information such as the timing of tests and symptom onset. This approach is  
 699 adopted as there is very little temporal information and what is available is poorly resolved.

700

701 Prior distributions for all parameters of the model are given below:

$$\begin{aligned}
 R_0 = \beta(\lambda^{-1} + \gamma^{-1}) &\sim \text{Gamma}(5, 1/3) \\
 \sigma^{-1} &\sim \text{N}(5 \cdot 56 - \lambda^{-1}, 0 \cdot 41^2) \\
 \lambda^{-1} &\sim \text{U}(0, 2) \\
 \gamma^{-1} - 1 &\sim \text{Gamma}(5, 3/5) \\
 r_s &\sim \text{Gamma}(5, 1/7) \\
 r_t &\sim \text{Gamma}(10, 1/9) \\
 p_a &\sim \text{Beta}(4, 8/3) \\
 p_c &\sim \text{Beta}(4, 8/3) \\
 \alpha &\sim \text{N}(1/2, 1/4), \text{truncated to } (-1.5, 1.5)
 \end{aligned}$$

702

703

704 The model priors for the average latent period and pre-symptomatic infectious periods ( $\sigma^{-1}$  and  $\lambda^{-1}$ ) were fitted  
 705 using data on exposure windows and symptom onset times from Lauer et al. (2020).<sup>5</sup> This distribution is  
 706 calculated using a particle marginal Metropolis Hastings method assuming a uniform [0,10] prior on  $1/\sigma$  (the  
 707 average exposed period), a uniform [0,10] prior on  $1/\lambda$  (the average pre-symptomatic infectious period) and  
 708 discrete uniform (1,15) shape parameters for each distribution. The resulting joint distribution on  $\sigma^{-1}$  and  
 709  $\lambda^{-1}$  was found to be well approximated by the parametric combination given above.

710

711 The prior for the average infectious period  $\gamma^{-1}$  was chosen with a mode of 3-4 days and a mean of 4 days. The  
 712 key quantity which arises from these temporal parameters is the generation time. The distribution for this was  
 713 obtained by sampling from the joint prior of the parameters ( $R_0, \sigma^{-1}, \lambda^{-1}, \gamma^{-1}$ ) and using simulation of the full  
 714 compartmental model in a fully susceptible population. The final size depends on the transmissibility and  
 715 generation time distribution, and the effective prior for the generation time distribution is shown in  
 716 Supplementary Figure 7.<sup>6</sup> This is consistent with the distribution reported in *Ferretti et. al (2020)*.<sup>7</sup>

717 Prior distributions were set on the relative susceptibility,  $r_s$  and transmissibility,  $r_t$  such that the prior  
718 distribution for  $r_s$  had mode 0.5 and the prior distribution for  $r_t$  has mode 1. Each of these distributions are  
719 relatively uninformative which captures the prior uncertainty in the parameter values surrounding the  
720 differences between children and adults in relation to transmission. The prior distribution on both the  
721 observation probabilities was centered around 0.6. The prior distribution on the effect of household size,  $\alpha$  was  
722 taken to be a Normal distribution with mean 0.5 and variance 0.25 truncated on the interval (-1.5, 1.5). This  
723 facilitates the possibility of density dependent transmission when  $\alpha = 0$  and frequency dependent transmission  
724 when  $\alpha = 1$ .

## 725 **References for supplementary information**

- 726 1 Black AJ, Geard N, McCaw JM, McVernon J, Ross JV. Characterising pandemic severity and  
727 transmissibility from data collected during first few hundred studies. *Epidemics*. 2017;19:61-73.  
728
- 729 2 Black, AJ. Importance sampling for partially observed temporal epidemic models. *Statistics and*  
730 *Computing*, 2019, 29, 617-630  
731
- 732 3 Walker JN, Black AJ, Ross JV. Bayesian model discrimination for partially-observed epidemic models.  
733 *Math Biosci*. 2019;317:108266.
- 734 4 Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using contact surveys and  
735 demographic data. *PLOS Computational Biology*. 2017;13(9):e1005697.  
736
- 737 5 Lauer SA, Grantz KH, Bi Q et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19)  
738 From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med*.  
739 2020;172(9):577-82.  
740
- 741 6 Ball F. A Unified Approach to the Distribution of Total Size and Total Area under the Trajectory of  
742 Infectives in Epidemic Models. *Advances in Applied Probability*. 1986;18(2):289-310  
743  
744
- 745 7 Ferretti L, Wymant C, Kendall M et al. Quantifying SARS-CoV-2 transmission suggests epidemic  
746 control with digital contact tracing. *Science*. 2020;368(6491):eabb6936.